**Abstract**

**Objectives:** Dosing schedule of antipsychotics has conventionally aimed at assuring constant delivery of the drug. However, there has been no study to examine fluctuation in positive symptoms within a day in relation to dopamine D2 blockade with antipsychotic drugs in patients with schizophrenia in their chronic phase of the illness, which was addressed in this study.

**Method:** Patients with schizophrenia (ICD-10) who had auditory hallucination and were receiving monotherapy with risperidone or olanzapine were included. Subjects were asked to record the time, frequency, and duration during 8 time periods (i.e. 00:00-03:00, 03:00-06:00, 06:00-09:00, 09:00-12:00, 12:00-15:00, 15:00-18:00, 18:00-21:00, and 21:00-24:00) for 3 days. Time and degree of peak and trough dopamine D2 receptor blockade with antipsychotics were calculated from 2 sparsely collected plasma drug concentrations for each subject, using our D2 prediction model. Frequencies and durations of auditory hallucinations were compared between the peak and trough time periods, using a paired t-test.

**Result:** 21 patients have participated in this study as of 31^st^ Jan 2016; the preliminary analysis included the data from 11 participants (11 inpatients; 7 men; age, 61.5 ± 9.2years; duration of illness, 36.4 ± 61.3 years; Positive and Negative Syndrome Scale total score, 70.2 ± 20.8). No significant difference was found in the frequency or duration of auditory hallucinations between the peak and trough time periods (frequency, 0.36 ± 0.50 vs. 0.45 ± 0.52; duration, 21.8 ± 30.3 vs. 27.3 ± 31.3 mins). A chi-squared test revealed that auditory hallucination occurred most frequently during the time period of 18:00-21:00 at 63.3% (p=0.03)

**Conclusion:** The results suggest that occurrence of auditory hallucinations was not related to dopamine D2 receptor blockage with antipsychotics within a day in patients with schizophrenia; rather, it seems to be associated with circadian rhythm. If this finding is confirmed in further investigations, it will have huge impact on the design of dosing schedule in the treatment of schizophrenia.
